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in FH was undertaken in 2004-2014 reviewing FH registries, PubMed and refer-
ence citations. Papers were assessed for bias using Newcastle-Ottawa scale. The 
literature-based FH relative risk (RR) was calculated. To validate the RR, a 10-year 
baseline risk of CV events was estimated for Rutherford-2 clinical trial population. 
The RR was used to adjust D’Agostino 2008 (primary prevention) and Wilson 2012 
(secondary prevention) baseline risk estimates. Sensitivity analyses varying patient 
characteristics were conducted. Results: Out of 796 identified publications, 14 
manuscripts met inclusion criteria. Danish population-based study (Benn 2012) 
showed the least risk of bias by directly comparing FH and non-FH populations in 
the same study and evaluating both fatal and non-fatal CV events. Subjects treated 
and untreated with lipid lowering therapy had odds ratio for coronary artery disease 
at 10.3 (95% CI: 7.8-13.8) and 13.2 (95% CI: 10.0 – 17.4), respectively. The FH RR of 
5.9 (5.0-6.9) and rate ratio of 7.1 (5.7-8.7) was calculated by pooling statin and no-
statin groups. Pooling the treated and untreated groups was introduced to mimic 
real world, accounting for the mix of primary and secondary prevention patients 
as well as different treatment paradigms. Combining the derived RR with the risk 
predicted by equations yielded a 55% 10-year baseline risk for Rutherford-2 FH 
patients. Patient characteristics such as proportion of patients receiving second-
ary prevention or age had an impact on estimated risk. ConClusions: Benn 2012 
provides estimates of increased CV risk for FH with the least bias. Estimated risk 
for Rutheford-2 patients is plausible for this high risk population. The derived RR 
seems acceptable for the use in economic modeling.
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objeCtives: To analyze survival and rehospitalization after a first hospitalization 
for heart failure (HF) in France. Methods: Analysis was based on EGB (“Echantillon 
Généraliste des Bénéficiaires”) database, a permanent random sample (1/97) of the 
French national healthcare insurance system database (SNIIRAM), linked with the 
national hospital discharge summary database (PMSI). Selected patients were adults 
(≥ 18 years) with a first HF hospitalization (ICD-10 codes: I-50/I-110/I-130/I-132) 
over a 3-years period (from 1st January 2009 to 31st December 2011). Patients were 
observed until death or 31stDecember 2013. Results: For analyses, 2,173 patients 
were included. Average age was 79 years (56% ≥ 80 years; 44% < 80 years) and sex 
ratio was close to parity (51% of woman; 49% of men). Average length of stay for 
the first HF hospitalization was 9.2 days (SD= 7.5 days) and 81% of these stays were 
strongly related to “heart failure or circulatory shock” (French DRG code: 05M09). 
The HF management was not optimal, with few cardiologist visits within the year 
prior the first HF hospitalization and low rates of prescription of HF recommended 
drugs. The median survival time was 37 months following the first HF hospitaliza-
tion and median time to rehospitalization was 15 months after the first HF hospi-
talization. The mortality and rehospitalization following the first HF hospitalization 
were both dramatically increased in older patients (≥ 80 years): respectively HR= 2.57 
(95%IC= [2.27-2.92]; p< 0.001) and HR= 1.68 (95%IC 1.51-1.87; p< 0.001). However, these 
events were both reduced in patients who visited a cardiologist during the year prior 
the first HF hospitalization: respectively HR= 0,84 (95%IC= [0.74-0.94]; p= 0.0036) and 
HR= 0.89 (95%IC= [0.80-0.99]; p= 0.0278). No significant difference on mortality or on 
rehospitalization was observed according to sex or treatments. ConClusions: 
Cardiologist visits remain at a very low frequency in this HF population. Better 
referring these patients to cardiologists should consolidate their management and 
thus reduce rehospitalization and mortality.
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objeCtives: More than 600,000 Canadians are afflicted with chronic heart fail-
ure (CHF), which is associated with high hospitalization and mortality rates. The 
objective of this study is to evaluate the mean cost ($CAD) and length of stay (LOS) 
amongst CHF patients treated in emergency departments (ED), stratified by sur-
vival and death outcomes. This abstract builds upon previously presented research 
to evaluate the costs of hospitalization due to CHF in a Canadian acute care set-
ting. Methods: Hospital discharge abstracts recorded between 2009 and 2013 from 
the Canadian Institute for Health Information’s Discharge Abstract Database and 
National Ambulatory Care Reporting System database were analyzed using a ret-
rospective cross-sectional study design. The two databases contain Canadian ED, 
acute care, and same-day surgery discharge abstracts. Discharge abstracts with 
congestive heart failure (ICD-10 code I50.0) recorded as the most responsible rea-
son for ED hospitalization amongst patients aged ≥ 18 were included in the study. 
Discharge abstracts with missing demographics, or absent without leave or against 
medical advice discharge status were excluded from the study. Results: 126,498 
ED discharge abstracts were included, with 99.8% of the visits ending in patient 
survival at discharge. The national mean CHF ED visit cost was $628, with survival 
outcomes incurring $628 and death outcomes incurring $502. The national mean 
CHF ED visit length of stay of was 0.56 days with survival outcomes requiring 0.57 
days and death outcomes requiring 0.16 days. The mean ED visit cost decreased with 
age with 18 to 34, 35 to 64, and 65+ incurring $670, $619, and $629 respectively. In 
contrast, the mean LOS increased with age: 18 to 34, 35 to 64 and 65+ experienced 
0.48, 0.50, and 0.58 days respectively. ConClusions: CHF ED visits are associated 
with significant healthcare cost and time investments, which provide an opportu-
nity for interventions that reduce the healthcare burden.
incremental net monetary benefit of £16 (£-406 to £329) at a willingness to pay of 
£20,000 per QALY. Dabigatran and apixaban had an incremental net monetary ben-
efit; £-320 (£-2,844 to £638) and £-686 (£-2,458 to £266) respectively. ConClusions: 
Rivaroxaban had the highest net monetary benefit at a willingness to pay threshold 
of £20,000 for primary prevention (THR and TKR). However, there was substantial 
uncertainty around these results in both populations.
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objeCtives: To evaluate the cost-effectiveness, from an Australian health sys-
tem perspective, of nivolumab versus ipilimumab for treatment of patients with 
previously-untreated, BRAF wild-type (WT) advanced melanoma (AM), comprising 
unresectable and/or metastatic melanoma). Methods: A state-transition Markov 
model with 3 health states (‘Alive, pre-progression’, ‘Alive, post progression’ and 
‘Dead’) and 12-week cycles was constructed to simulate the history of BRAF-WT 
Australian patients with AM. A 5% annual discount rate was applied to costs and 
health measures. A 10-year time horizon was selected to capture the long-term 
survival achieved with immunotherapy agents. For the Nivolumab Group, risks of 
progression and death were based on those observed in the Nivolumab arm of 
study CA209-066 (nivolumab versus dacarbazine). Log-logistic functions were used 
to extrapolate trial data up to 10 years based on AIC and clinical plausibility. For 
the Ipilimumab Group, transition probabilities were derived from applying hazard 
ratios (HRs) to the corresponding transition probabilities in the Nivolumab Group. 
In the absence of head-to-head evidence, HRs were calculated by indirect compari-
son of nivolumab versus ipilimumab using published data. AM management costs 
were estimated by survey of Australian clinicians. Ipilimumab costs were based on 
prices reimbursed under the Pharmaceutical Benefits Scheme (PBS) of Australia.
Nivolumab costs were based on the expected reimbursed price under the PBS per 
course of treatment. Utilities were determined using EQ-5D data from study CA209-
066. Probabilistic sensitivity analyses were undertaken using variations to key input 
parameters. Results: Compared to ipilimumab, nivolumab therapy over 10 years 
would lead to an improvement in survival of 1.58 years and 1.30 QALYs per per-
son, at a (discounted) net cost of AUD$77,119 per person. These equate to ICERs of 
AUD$48,851 per year of life saved and AUD$59,311 per QALY saved. ConClusions: 
Compared with ipilimumab, nivolumab represents a cost-effective means of improv-
ing outcomes among Australian patients with AM.
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objeCtives: Aclidinium/formoterol 400/12 µg (FDC 400/12 µg), is a long-acting mus-
carinic antagonist (LAMA) and a long-acting β 2-agonist (LABA) in a fixed-dose com-
bination used in the management of patients with chronic obstructive pulmonary 
disease (COPD). This study aimed to assess the cost-effectiveness of FDC 400/12 µg 
against the LAMA, aclidinium bromide 400 µg (AB 400 µg). Methods: A 5 health 
state Markov transition model, with monthly cycles, was developed using MS Excel 
to simulate the clinical course of patients with moderate to severe COPD treated with 
FDC 400/12 µg versus AB 400 µg. Health states were based on severity levels defined 
by GOLD 2010 criteria. The analysis was a head to head comparison without step-
up-therapy, from the NHS Scotland perspective, over a 5 year time horizon. Clinical 
data on the initial lung function improvement was provided by a pooled analysis of 
the ACLIFORM and AUGMENT trials. Resource use (management and event costs) and 
utilities were health state specific. Costs and effects were discounted at an annual 
rate of 3.5%. The outcome of the analysis was cost (£) per quality adjusted life year 
(QALY) gained. The analysis included one way and probabilistic sensitivity analyses 
to investigate the impact of parameter variability on model outputs. Results: FDC 
400/12 µg provided marginally higher costs (£41) and more QALYs (0.014), resulting 
in an incremental cost-effectiveness ratio of £2,976. Sensitivity analyses indicated 
results were generally robust to key parameter variation. The main drivers were mean 
baseline FEV1, risk of exacerbation, FEV1 improvement of FDC 400/12 µg and lung 
function decline. The probability of FDC 400/12 µg be cost-effective (using a willing-
ness to pay threshold of £20,000/QALY) versus AB 400 µg was 79%. ConClusions: 
In the Scottish setting, aclidinium/formoterol 400/12 µg can be considered a cost-
effective treatment option in patients with COPD versus aclidinium 400 µg.
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objeCtives: To derive an estimate for increased cardiovascular (CV) risk in familial 
hypercholesterolemia (FH) patients for use in economic analyses. Methods: A 
literature search reporting CV risk, rates, odds or ratios of mortality and morbidity 
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We identified 11,602 patients receiving chemotherapy in public hospitals. During 
follow-up, 7,417 patients (63.9%) received expensive drugs at least once, including 
mostly pemetrexed (57.5%), bevacizumab (16.9%), or topotecan (7.2%); these patients 
were significantly more likely women and younger than the rest of the cohort 
(p< 0.0001). Conversely, all selected comorbidities were associated with lower rates 
of administration i.e. chronic renal failure, diabetes, hypertension, COPD and other 
respiratory diseases (p< 0.0001). Taking as reference patients from affluent areas, we 
observed lower rates of access in intermediary affluent, intermediary deprived and 
deprived areas. After multivariate adjustment, odd ratios were 0.85 [95%:0.75–0.95], 
0.82 [95%:0.74–0.92] and 0.80 [95%:0.71–0.89], respectively. ConClusions: Even in 
a health care system organized to ensure a high degree of equity in medical care, 
we found indications of a socioeconomic gradient in innovative anticancer drugs 
access in lung cancer.
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objeCtives: Tight public budget constraints have accelerated the debate on the 
extent of prescribed medications that are publicly covered in Spain, a country with 
one of the lowest percentage of OTC sales over total drugs sales. The objective 
of this study is to examine the economic impact of payer policies consisting on 
a hypothetical Rx-to-OTC switch of 5% of currently publicly covered prescription 
drugs for mildest conditions. Methods: A decision model is used to estimate the 
economic impact of the switch. Both third-party-payer and societal perspectives 
are adopted, using a five-year timeframe, both at regional (17 regions) and national 
levels. The model is inspired by a previous ones in European countries, but the 
timeframe and the effects measured have been further developed for the sake of 
robustness and better reflection of the current Spanish reality. The effects, meas-
ured in monetary units, include those regarding to quality of primary care, labor 
productivity, the opportunity cost for non-working populations, and financial bur-
den of pharmaceutical expenditure. Resources allocated to improving responsible 
self medication are also accounted for. The study analyses the effects on different 
stakeholders (patients, NHS, and society). Finally, it includes both a standard and 
a probabilistic sensitivity analysis. Results: The switch results in a 3.125€ millon 
societal effect, explained by improving quality of primary health care (2.258M€ ), 
improving labor productivity (507), optimization of non working patients’time (579) 
and a reduction of public expenditure on publicly covered medication (979). On 
the other hand, there are negative effects from increasing privately funded drugs 
(1.165) and the cost of improving self-care (35). Sensitivity analyses confirm overall 
results (p< 0,01). ConClusions: Under increasing budgets constraints, switch-
ing drugs for mild conditions may be a solution with positive societal net effects, 
although the distribution of the impacts among stakeholders might make the ini-
tiative unpopular.
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objeCtives: Since the introduction of orphan legislation the number of orphan 
drugs has dramatically increased. The objective of the study is to compare 
orphan designations and approvals in the EU, USA and Japan. Methods: The 
list of molecules with orphan status, as well as the list of approved orphan drugs 
(ODs) in the USA, EU and Japan were identified from the websites of Food and 
Drug Administration (FDA) of the USA, the European Medicines Agency (EMA), and 
National Institute of Biomedical Innovation, Health and Nutrition. All available 
details on orphan designations and approvals were extracted. Results: By June 
2015, 3465 orphan designations were granted in the USA, 1503 in the EU and 399 
in Japan. More than 60% of orphan designations led to an approval in Japan, about 
14% in the USA, and only 7% in the EU. The median delay between granting an 
orphan designation and approval was more than three years in the USA and EU, 
and about two years in Japan. EMA publishes the most detailed information on 
orphan designations and OD approvals. Unlike the USA and Japan, the details on 
refusals in orphan status or approvals together with decision rationale are available 
in the EU. ConClusions: A higher number of ODs has been approved in the USA. 
However, many of them have been discontinued, particularly among ODs approved 
before 2000. The relatively small number of ODs approved in the EU might be related 
to the lower financial support of ODs provided in the EU compared to the USA and 
Japan. A noticeably high commercialisation rate is observed in Japan, which can be 
associated with the feasibility criteria applied to the drugs submitting for orphan 
designation on the one hand, and with the arrival on Japan market of molecules 
already commercialized in other countries on the other.
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objeCtives: The objectives are to present the scorecard HTA system used in Romania 
from July 2014 and the results in terms of access of new therapies at reimburse-
ment. Methods: The authors studied the scorecard HTA legislation and the relation-
ship with the health-care environment from the last 2 years considering: the evolution 
of the Romanian HTA methodologies, the HTA process and the implications in other 
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objeCtives: Patient registries are a good source of evidence for health-care pro-
viders, payers and regulators requiring real-world data for evidence-based deci-
sion making. This review aimed to identify and assess key characteristics of the 
heart failure (HF) registries reporting patients’ data from five European Union (EU5) 
countries. Methods: HF registries were identified through a systematic search of 
Embase and PubMed databases. Inclusion criteria were data on HF patients from 
EU5 countries (France, Germany, Italy, Spain, and the UK) and patient counts ≥ 1000. 
Registry publications and websites were assessed for availability of information on 
patient characteristics, disease management, resource use, treatment outcomes and 
funding agency. Results: Of 23 identified registries reporting data for HF patients, 
43% were multinational while 57% were national-level registries. Twelve registries 
each collected data from Spain, Germany, and Italy and eight and six registries from 
France and the UK, respectively. Data was collected for patients with acute HF only 
(31%), chronic HF only (43%), and both acute and chronic HF (26%) in the identified 
registries. Number of included patients varied from 1037 to 25,000 with the average 
follow-up ranging from 3-53 months. Data was available for patient demographics 
(in 100% registries), comorbidities (87%), diagnosis and disease classification (78%), 
mortality (78%), hospitalisation (96%), prescribed drugs (100%), and patient-reported 
outcomes (17%). Registries also collected data on specific diagnostic tools (blood 
pressure, ECG, blood tests, biomarkers, imaging, and renal function tests), treat-
ment procedures (revascularisation, catheterization, and transplant), resource use, 
adverse events, and cost. Of these registries, 65% initiated during last 10 years and 
61% were industry-funded. ConClusions: Registries are a rich source of real-
world information on HF patients which can be turned into actionable insights 
for important health-care decisions. Rise in the number of HF registries in recent 
years and industry funding indicates increased interest of stakeholders in these 
registries’ data.
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objeCtives: In April 2014, the European Medicines Agency (EMA) announced an 
adaptive pathways pilot enabling initial approval of a medicine for a restricted 
patient population with very high unmet need based on early clinical studies. 
Progressive adaptations of the marketing authorisation would expand access to 
broader patient populations based on subsequent data. However, such an adaptive 
license may pose a problem for payer bodies, many of which currently require a 
long time period to review medicines under strict clinical and economic criteria. 
This research aims to evaluate how ready major European current payer systems 
would be to encompass EMA adaptive pathways. Methods: Key European payer 
bodies from the EU5 (NICE, SMC, HAS, IQWiG/G-BA, AIFA and AEMPS were scored by 
PAREXEL’s Commercialization panel of pricing and reimbursement experts on 4 key 
criteria: (1) speed of appraisal, (2) flexibility to clinical data appraisal approach, (3) 
flexibility to economic data appraisal approach, and (4) no additional local/regional 
access hurdles as either high (2 points), medium (1 point) or low (0 points). Results: 
Out of a possible 8 points, HAS scored the highest (7) followed by SMC (6), AIFA (5), 
AEMPS (5), IQWiG (4) with NICE the lowest (2). Low scores for NICE were driven by 
its long duration for decision-making alongside rigid adherence to ICER thresholds. 
Higher scores for SMC were based on their much faster appraisals and flexibil-
ity through the new PACE process. AIFA and AEMPS both scored moderately with 
positive flexibility in their approaches tempered by additional local/regional access 
hurdles. In Germany, rigid adherence to direct comparative trial data versus the 
relevant comparator limited positive scoring. ConClusions: some payers (most 
notably NICE) will need to make significant changes to their appraisal processes 
In order for early market approval under adaptive pathways to translate into early 
reimbursement and payer access
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objeCtives: Lung cancer survival is socioeconomically patterned, and socioeco-
nomic inequalities in receipt of treatment have been demonstrated in several coun-
tries. In the hospitals, many innovative anticancer drugs are too expensive to be 
funded through a Diagnosis-Related Group (DRG) of chemotherapy administration. 
In France, such drugs are fully reimbursed up to national reimbursement tariffs 
(extra-DRG funding) to ensure equity of access. Our aim was to analyze the access 
of patients to innovative drugs according to social deprivation index. Methods: 
A retrospective cohort study was constituted with all patients having a diagnosis 
of metastatic lung cancer in the French National hospitals databases (PMSI) during 
year 2011. Patients’ data were linked to allow a two-year follow-up period. Because 
extra-DRG data were not available for private hospitals, our analysis was restricted 
to patients benefiting from chemotherapy in public hospitals only. In addition 
of demographic characteristics, comorbidities, and treatment, we assigned each 
patient to social deprivation index based on their postcode of residence. Results: 
